The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000440325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/03/2026
Date registered
Help: Date registered
9/04/2026
Date last updated
Help: Date last updated
9/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating the feasibility and performance of CRISPR point-of-care testing for the diagnosis of gonorrhoea and chlamydia in adults presenting for sexually transmissible infection testing
Scientific title
Evaluating the feasibility and performance of CRISPR point-of-care testing for the diagnosis of gonorrhoea and chlamydia in adults presenting for sexually transmissible infection testing
Additional trial identifiers [1] 315871 0
Nil
Universal Trial Number (UTN)
Trial acronym
CRISTI-NG
Related trial records

Health condition
Health condition(s) studied:
gonorrhoea 339628 0
chlamydia 339629 0
sexually transmissible infections 339630 0
Condition category
Condition code
Infection 335875 335875 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
This observational study evaluates the accuracy and feasibility of using a novel Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based point-of-care diagnostic platform for detecting Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) in consecutive symptomatic adults attending sexual health clinics across a 12 month period. The point-of-care testing platform detects each pathogen through targeting two independent genomic regions through isothermal amplification and CRISPR-Cas reaction using Cas12a and Cas13a, each with distinct fluorescent reporters, and the fluorescence intensities are measured with the T8-ISO instrument. Training in performing the CRISPR point-of-care test will be provided by the University of Melbourne research team who have developed the assay, Trained staff may subsequently train other staff members to perform the test after competency in the testing procedure has been confirmed,

The point-of-care instrument will be located in a non-clinical area within sexual health clinics and testing will be performed by a trained staff member (e.g. nurses, research assistants etc.) on the same day as participant sample collection. The samples assessed will be urine, and if collected, genital swabs. Participant interaction is complete at the time of sample collection, participants will not receive the results of the point-of-care test. Test results are available from the point-of-care test after approximately 40 minutes with the point-of-care device visually displaying a positive, negative or invalid result. Results are also stored on the device and will be exported via spreadsheet to review the device logs for accuracy of recorded result.
Intervention code [1] 332475 0
Diagnosis / Prognosis
Description of the comparator or control
All participant will have both CRISPR point-of-care testing (investigational test) and laboratory standard of care testing (reference test) performed on their samples collected during the clinic visit. This diagnostic accuracy study will compare results from the CRISPR point-of-care test (investigational test) directly with those from the laboratory test (reference test).
Control group
Active

Outcomes
Primary outcome [1] 343392 0
Detection of Neisseria gonorrhoeae using novel CRISPR point-of-care test compared to standard laboratory diagnostics tests for Neisseria gonorrhoeae
Timepoint [1] 343392 0
Assessed once on participant sample collected at enrolment
Primary outcome [2] 343393 0
Detection of Chlamydia trachomatis using novel CRISPR point-of-care test compared to standard laboratory diagnostics tests for Chlamydia trachomatis
Timepoint [2] 343393 0
Assessed once on participant sample collected at enrolment
Primary outcome [3] 344429 0
Detection of a genomic marker in Neisseria gonorrhoeae predictive of antimicrobial resistance to ciprofloxacin using novel CRISPR point-of-care test compared to standard laboratory diagnostics tests for ciprofloxacin resistance.
Timepoint [3] 344429 0
Assessed once on participant sample collected at enrolment
Secondary outcome [1] 454330 0
Time to diagnosis using novel CRISPR point-of-care test compared to standard laboratory diagnostics tests
Timepoint [1] 454330 0
Assessed once on participant sample collected at enrolment

Eligibility
Key inclusion criteria
Symptomatic (urethritis or vaginal symptoms consistent with possible gonorrhoea and/or chlamydia infection) individuals presenting at sexual health clinics for sexually transmissible infection testing
Aged 18 and older
Able to provide informed written consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Asymptomatic individuals/ persons unlikely (as judged by the clinician) to have gonorrhoea and/or chlamydia infection
Individuals unwilling to provide samples for diagnostic testing

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NT,VIC
Recruitment hospital [1] 28782 0
Melbourne Sexual Health Centre (MSHC) - Carlton
Recruitment hospital [2] 28783 0
Clinic 34 - Darwin City - Darwin City
Recruitment postcode(s) [1] 45015 0
3053 - Carlton
Recruitment postcode(s) [2] 45016 0
0800 - Darwin City

Funding & Sponsors
Funding source category [1] 320464 0
Government body
Name [1] 320464 0
Australian Government Department of Health, Blood Borne Viruses and Sexually Transmissible Infections Research Program Grant
Country [1] 320464 0
Australia
Primary sponsor type
University
Name
University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 323083 0
None
Name [1] 323083 0
Address [1] 323083 0
Country [1] 323083 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319015 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319015 0
Ethics committee country [1] 319015 0
Australia
Date submitted for ethics approval [1] 319015 0
15/04/2025
Approval date [1] 319015 0
14/05/2025
Ethics approval number [1] 319015 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 145990 0
Prof Catriona Bradshaw
Address 145990 0
Melbourne Sexual Health Centre, 580 Swanston St, Carlton VIC 3053
Country 145990 0
Australia
Phone 145990 0
+61 3 9341 6253
Fax 145990 0
Email 145990 0
Contact person for public queries
Name 145991 0
Jacqueline Prestedge
Address 145991 0
University of Melbourne at the Doherty Institute, 792 Elizabeth St, Melbourne VIC 3000
Country 145991 0
Australia
Phone 145991 0
+61 423 058 582
Fax 145991 0
Email 145991 0
Contact person for scientific queries
Name 145992 0
Shivani Pasricha
Address 145992 0
University of Melbourne at the Doherty Institute, 792 Elizabeth St, Melbourne VIC 3000
Country 145992 0
Australia
Phone 145992 0
+61 423 058 582
Fax 145992 0
Email 145992 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.